ReviewJournal of comparative effectiveness research2015
Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Review in Journal of comparative effectiveness research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of using cilostazol versus aspirin in secondary stroke prevention: systematic review and meta-analysis of randomised controlled clinical trials.Internal medicine journal · 2025Pooled it
- Perioperative Antithrombotic Strategies in Vascular Surgery: A Survey in Germany.Health science reports · 2025Article
- Cost-effectiveness of short-protocol emergency brain MRI after negative non-contrast CT for minor stroke detection.European radiology · 2022Article
- Intracranial Arterial Calcifications: Potential Biomarkers of Stroke Risk and Outcome.Frontiers in neurology · 2022Review
- Frequency of Aspirin Resistance in Ischemic Stroke Patients and Healthy Controls from Colombia.Stroke research and treatment · 2021Article
- Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology.Frontiers in cardiovascular medicine · 2021Review
- Comparison of the flexible parametric survival model and Cox model in estimating Markov transition probabilities using real-world data.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the cornerstone of secondary stroke prevention, and proven drugs available to successfully realize this therapeutic strategy for the long term include aspirin, dipyridamole plus aspirin and clopidogrel. However, government agencies, corporations, health plans and patients desire more information about the clinical- and cost-effectiveness of these established therapies in real-world settings. This paper provides an update on evidence-based secondary stroke prevention with antiplatelet medications, discusses cost-related issues and offers perspective about the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.